Kevin Kunzmann

Lawrence Eichenfield, MD, discusses recent achievements in identifying and possibly preventing atopic dermatitis development in infants.

Yale dermatologist Christopher Bunick, MD, PhD, discusses the recurring issue with increased levels of the carcinogen found in self-care and cosmetic products.

With dupilumab already available and JAK inhibitors on the way, clinicians have a bevy of treatments designated for pediatric patients.

In consideration of emerging JAK inhibitor options, and the current prescribing availability of baricitinib.

New open-label extension data support the long-term use of the systemic therapy in patients with moderate-to-severe disease.

Brett King, MD, PhD, explains the altered screening and care strategies for patients following baricitinib's approval.

Real-world analysis comparing systemic therapies show dupilumab better improves EASI and quality of life among affected children.

Brett King, MD, PhD, discusses the newly available JAK inhibitor—the first systemic therapy approved for the hair-loss condition.

Data from the ongoing TARGET-DERM AM observational study show patients with more exposed disease have generally worse severity and challenges linked to quality of life.

The JAK inhibitor received FDA approval for vitiligo this summer. Investigator now see it as a potent non-steroidal option for eczema.

Christopher Bunick, MD, discusses the future progress of acne management—including a potential mRNA vaccine current in development.

New 16-week data from the SPROUT trial show the PDE4 inhibitor may be highly efficacious in chilren and adolescents.

The novel OX40 inhibitor showed significant efficacy in 4 different doses versus placebo in Fall Clinical Dermatology data.

With a broadening array of drug options, involving patients in the care process may be a key to adherence and long-term success.

Pooled data from 7 clinical trials show the IL-23 inhibitor is not associated with worsened risk of adverse events or infections.

Christopher Bunick, MD, PhD, reviews the benefit of antibiotic resistance, blood-brain barrier penetration, and digestive distress with agents like sarecycline.

Peter Lio, MD, shares his strategy for advancing severely impacted patients from systemic therapy to either upadacitinib or abrocitinib.

A dermatologist considers what the orally-administered TYK2 inhibitor will provide eligible adult patients.

Data from the phase 3 LIMMitless show patients received long-term benefit from the biologic, regardless of baseline demographic or disease status.

Peter Lio, MD, explains firsthand how abrocitinib and upadacitinib became the latest options for his most difficult-to-treat patients.

Raj Chovatiya, MD, PhD, reviews the clinical progression of tapinarof and roflumilast cream headed into the 2022 Fall Clinical.

New analyses suggest insomnia symptoms among older patients may play a pivotal role in the relationship between objective and self-reported cognition.

A cross-sectional analysis from the France COVID-19 lockdown period resulted in a predictive model for insomnia risk.

A retrospective analysis of controlled drug dispensation shows conflicting rates of prescriptions to teenagers and young adults.

The approval indicates the subcutaneous loop diuretic for the at-home treatment of congestion in adults with NYHA Class II/III chronic heart failure.

New data suggest transparency regarding drug safety regulatory response has not been consistent in recent years.

A new analysis suggests raise levels of zinc, iron, lead and aluminum—linked to cigarette use—is positively correlated with insomnia.

Martha Gulati, MD, joins The Heart Team to share her professional experiences and recommendations in treating female-specific cardiovascular disease.

Martha Gulati, MD, joins episode 2 to discuss the burden of gender disparity in cardiovascular research, screening and care.

New data from AAO 2022 show how technology may refine a currently inefficient enrollment practice for retina disease assessment.